# Developing Oral LT3 Therapy for Heart Failure - HFrEF

> **NCT04112316** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 28 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Low T3 Syndrome

## Interventions

- **DRUG:** Liothyronine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04112316
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-11
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04112316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04112316, "Developing Oral LT3 Therapy for Heart Failure - HFrEF". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04112316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*